60325 Frankfurt am Main, de
Gimv invests EUR 24.1 million and divests EUR 7.9 million in the first months of FY 2011-2012
In addition, Gimv will also report on the realised investments and divestments in the first months of the financial year. Moreover, Gimv will also comment on the developments within the co-investment funds.
In the first months (1 April 2011 to 27 June 2011) of FY 2011-2012 Gimv has invested EUR 24.1 million and realised exits totalling EUR 7.9 million.
In these first months Gimv has invested EUR 24.1 million EUR (on Gimv's balance sheet). EUR 13.5 million (56%) of this amount has been invested within Buyouts & Growth (Belgium, Netherlands, France and Germany), EUR 10 million (42%) in Venture Capital (Technology, Life Sciences and Cleantech) and the remaining EUR 0.6 million EUR (2%) in co-investment funds (Gimv-XL, DG Infra+, DG Infra Yield and Gimv-Agri+). The main investments over the past months were the new investment in Multiplicom and the follow-on investments in Alfacam, Ambit, GreenPeak, Ubidyne and Human Inference. Besides these investments on its balance sheet Gimv also made additional investments within the co-investment funds for an amount of EUR 7.8 million.
The divestments (on Gimv's balance sheet) currently amount to EUR 7.9 million. EUR 6.1 million of this amount (77%) has been achieved within Buyouts & Growth and EUR 1.8 million (23%) within Venture Capital. The main divestment of the past months was ADA Cosmetics. Besides the divestments on its own balance sheet Gimv also realised exits in the funds under management for EUR 26.0 million.
Following the dividend payment on 7 July 2011 (but before the Scana Noliko and PinguinLutosa transactions) Gimv will have an expected net cash position of approximately EUR 150 million.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.